MLND - Millendo Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
-203
0
295
653
Cost of Revenue
-
-
790
5,401
Gross Profit
-
-
-495
-4,748
Operating Expenses
Research Development
27,223
14,425
18,337
21,641
Selling General and Administrative
14,479
12,449
27,744
49,223
Total Operating Expenses
41,702
26,874
46,081
70,864
Operating Income or Loss
-41,695
-26,874
-46,576
-75,612
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
3,312
-169
-5,084
-7,106
Income Before Tax
-38,294
-27,177
-50,908
-82,059
Income Tax Expense
-
-
67
201
Income from Continuing Operations
-38,294
-27,177
-50,975
-82,260
Net Income
-38,309
-27,192
-50,975
-82,260
Net Income available to common shareholders
-38,309
-27,192
-50,975
-82,260
Reported EPS
Basic
-
-17.58
-21.45
-38.40
Diluted
-
-17.58
-21.45
-38.40
Weighted average shares outstanding
Basic
-
1,547
2,378
2,143
Diluted
-
1,547
2,378
2,143
EBITDA
-
-26,842
-44,926
-73,374